Online visual acuity test gains FDA clearance

Article

The web-based, self-guided software application is accessed through touchscreen mobile devices.

An online visual acuity test, the Visibly Digital Acuity Product (VDAP) (Visibly, Inc.), recently gained clearance from the Food and Drug Administration (FDA).1

The FDA described the VDAP as a web-based, self-guided software application that consumers can access using a touchscreen mobile device and internet-connected computer.

Adults aged 22 to 40 years who can perform an in-home self-test can use the test to help evaluate visual acuity, the FDA said.

According to the FDA website, “The application’s recommendations are intended to be supportive recommendations that will be used by an eye care provider, along with the patient’s medical history and profile, prior corrective eyewear prescriptions, and subjective vision data. This device does not provide screening or diagnosis of eye health or other disease and does not replace an eye health exam with a licensed provider.”

After the patient completes the test, the vision results are sent eye care professionals to evaluate and follow-up with the patient, for corrective lens prescription renewal online or referral for an in-person eye examination.

Reference
1. Larkin H. JAMA. Online visual acuity test cleared. 2022;328(13):1290. doi:10.1001/jama.2022.15443
Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
© 2025 MJH Life Sciences

All rights reserved.